Tamtam Try Tamtam free
The Cigna Group logo

The Cigna Group account plan

global health insurance provider

At a glance

The Cigna Group is a U.S. health company (Evernorth, Cigna Healthcare) with 2025 revenues of $274,900 million and about 67,700 employees.

The Cigna Group, headquartered in Bloomfield, Connecticut, combines a pharmacy and health services business, Evernorth Health Services, with a health benefits business, Cigna Healthcare. It sells pharmacy benefit management, specialty pharmacy, care services and employer medical plans to health plans, employers, unions and government programmes; revenues from U.S. external customers were 98% of the total in 2025. Total 2025 revenues were $274,900 million (+11%), shareholders' net income $5,957 million and adjusted income from operations $8,014 million ($29.84 per share). It employed approximately 67,700 people at the end of 2025 and served more than 185 million customer relationships. Brian Evanko led the group as President and CEO by July 2026; David M. Cordani was Chairman and CEO at the time of the 10-K in February 2026.

Business units

Strategic priorities

10% to 14% EPS growth through 2030
The long-term framework combines 6% to 9% average annual income growth with 4% to 5% EPS accretion from capital deployment, with an adjusted EPS floor of $45 per share by 2030.
Grow specialty pharmacy
Specialty is to exceed 40% of group earnings by 2030, with 8% to 12% long-term annual earnings growth and about $20 billion of new distribution revenue by 2030.
Rebate-free pharmacy benefits (Signature)
Upfront discounts at the counter for Cigna Healthcare fully insured customers from 2027 and the standard for Evernorth clients from 2028, with at least 50% of members on Signature models by end 2028.
Employer health plans, Select first
Cigna Healthcare targets 6% to 9% earnings growth, a 10% Select market share by 2030 and another 10% improvement in unit cost position.
Productivity and AI
A $3 billion modernization and productivity programme from 2026 through 2030 covers workflow automation, AI, talent and supplier optimisation, on top of the strategic optimization program targeting at least $500 million of annualized after-tax savings.

Latest results

In Q2 2026 total revenues rose 7% to $71,668 million and adjusted income from operations rose 6% to $2,054 million, or $7.78 per share. Evernorth's adjusted revenues grew 6% to $61,468 million but its pre-tax adjusted income fell 2%, as Specialty and Care Services (+22%) offset Pharmacy Benefit Services (-27%). Cigna Healthcare's pre-tax adjusted income rose 17% with an MCR of 84.5%. Pharmacy customers fell 4% to 118.2 million while medical customers rose 2% to 18.4 million. Full-year 2026 guidance was raised to adjusted income from operations of at least $30.45 per share and reaffirmed at the September 30, 2026 Investor Day.

Investments and deals

Shields Health Solutions
In Q3 2025 the company invested $3.5 billion in preferred stock of Shields, which runs specialty pharmacies for over 80 health systems.
Medicare divestiture
Medicare Advantage, stand-alone drug plans, supplemental benefits and CareAllies were sold to Health Care Service Corporation on March 19, 2025 for final cash proceeds of $4.9 billion, mostly used for buybacks.
Technology capex
Capex was $1.2 billion in 2025 and about $1.3 billion is planned for 2026, mainly technology.
AI partnerships
Sierra provides conversational and voice AI, and a collaboration with OpenAI on clinical AI starts with oncology; Pharmacy Forward is expected to cut time to therapy in half.
Capital return
About $50 billion of operating cash flow is expected in 2026-2030, with 55% to 60% for buybacks, debt repayment and M&A focused on bolt-ons.

Challenges and risks

PBM regulation
The Consolidated Appropriations Act, 2026 requires PBMs to remit 100% of certain rebates and fees to ERISA plan sponsors from August 2028 and adds Part D rules from 2028 and 2029.
Pressure on Pharmacy Benefit Services earnings
Large-client renewals through the end of the decade and Signature transition spending weigh on PBS income in 2026 and 2027; one client is about 19% of total revenues.
Elevated medical cost trends
Management sees high single digit cost trends driven by brand drug and hospital prices, and assumes elevated trend through 2026 and 2027.
Lower GLP-1 volumes
GLP-1 growth is moderating as coverage declines, and the Q2 2026 Evernorth outperformance is expected to be given back in the second half.
Litigation and AI scrutiny
Risks include litigation alleging improper use of AI in claims evaluation, cybersecurity, and goodwill and intangibles of about $73.5 billion.

What leadership says

“affordability continues to be the most pronounced problem across the health care space”

Brian Evanko, President and Chief Executive Officer · Q2 2026 earnings call, July 30, 2026

“By harnessing technology, data and AI to deliver more personalized experiences, improve access and lower costs, we are creating greater value every day.”

Brian Evanko, President and Chief Executive Officer · Q2 2026 earnings release, July 30, 2026

“This is not about replacing clinicians with technology but helping clinicians spend more time where they can make the greatest difference.”

Brian Evanko, President and Chief Executive Officer · Q2 2026 earnings call, July 30, 2026

“We use AI to augment but never to replace clinical expertise.”

Dr. Amy Flaster, Chief Medical Officer · 2026 Investor Day, September 30, 2026

Where a supplier can help

Automation for the $3 billion programme
The modernization and productivity programme names workflow automation, AI and supplier optimisation, which opens doors for process automation, AI tooling and outsourcing vendors.
Signature rollout
Moving clients to the rebate-free model by 2028 needs claims system changes, pharmacy pricing analytics and client communication support.
Specialty distribution growth
The target of about $20 billion of new distribution revenue by 2030 and a fifth clean room under construction point to cold-chain logistics, pharmacy automation and compliant facility suppliers.
Compliance with PBM rules
The Consolidated Appropriations Act, 2026 remittance and Part D rules call for reporting, audit and transparency tooling for plan sponsors.
Employer affordability tools
With affordability the main employer concern and Select growth a priority, benefits navigation, cost transparency and care management solutions fit Cigna Healthcare's offer.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like The Cigna Group?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about The Cigna Group

What does The Cigna Group do?

It runs Evernorth Health Services, which covers pharmacy benefits (Express Scripts), specialty pharmacy (Accredo) and care services, and Cigna Healthcare, which provides employer medical plans and international health cover.

What is The Cigna Group's revenue?

Total revenues were $274,900 million in 2025, up 11%. Q2 2026 revenues were $71,668 million.

How many employees does The Cigna Group have?

Approximately 67,700 people at the end of 2025, about 88% of them in the United States.

What is The Cigna Group's strategy?

It targets 10% to 14% EPS growth through 2030 by growing specialty pharmacy, moving pharmacy benefits to the rebate-free Signature model, expanding employer plans in the Select market and using AI for productivity.

Who leads The Cigna Group?

Brian Evanko is President and Chief Executive Officer, and Ann Dennison is EVP and CFO.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)